We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




AI Accurately Predicts Cancer Outcomes from Tissue Samples

By LabMedica International staff writers
Posted on 27 Dec 2023
Print article
Image: The AI model analyzes cell spatial organization to make patient diagnoses and prognoses (Photo courtesy of UT Southwestern)
Image: The AI model analyzes cell spatial organization to make patient diagnoses and prognoses (Photo courtesy of UT Southwestern)

Patient tissue samples are commonly examined on slides by pathologists, a process integral to diagnosis. This traditional method, while effective, is notably time-intensive and subject to variability in interpretations among different pathologists. Moreover, some subtle details in pathology images might escape human observation but could hold critical insights into a patient's health status. Over recent years, several artificial intelligence (AI) models have been developed to undertake certain tasks typically performed by pathologists, such as classifying cell types or gauging cellular interactions based on proximity. Nevertheless, these models have not fully captured the more intricate aspects of tissue image analysis that pathologists conduct, including recognizing complex cell spatial arrangements and filtering out irrelevant image 'noise' that could distort interpretations. Addressing this gap, researchers have now introduced an innovative AI model that is capable of examining the spatial organization of cells within tissue samples, offering precise predictions about cancer patient outcomes and offering new prospects for AI-assisted cancer prognosis and tailored treatment plans.

Dubbed Ceograph, this AI tool, created by researchers at UT Southwestern Medical Center (Dallas, TX, USA), mimics the approach taken by pathologists for examining tissue slides. It begins by identifying cells and their respective positions within the image. It then classifies cell types and delineates their shapes and spatial distributions, creating a comprehensive map where the arrangement, dispersion, and interactions among cells are detailed for analysis. The team validated Ceograph in three clinical scenarios using pathology slides. In one instance, Ceograph distinguished between two lung cancer types: adenocarcinoma and squamous cell carcinoma. In another, it gauged the progression risk of potentially cancerous oral conditions to malignancy. Finally, it identified lung cancer patients most likely to benefit from epidermal growth factor receptor inhibitors.

In each scenario, Ceograph's performance in predicting patient outcomes surpassed traditional methods. Notably, the cell spatial organization insights provided by Ceograph are not only interpretable but also shed light on the biological implications of varying individual cell-cell spatial interactions. These developments highlight the increasingly vital role AI can play in healthcare, particularly in enhancing the precision and efficiency of pathology analyses. This technology promises to refine preventive strategies for individuals at high risk and tailor treatment choices to meet each patient's unique needs.

“Cell spatial organization is like a complex jigsaw puzzle where each cell serves as a unique piece, fitting together meticulously to form a cohesive tissue or organ structure,” said study leader Guanghua Xiao, Ph.D. “This research showcases the remarkable ability of AI to grasp these intricate spatial relationships among cells within tissues, extracting subtle information previously beyond human comprehension while predicting patient outcomes.”

Related Links:
UT Southwestern Medical Center 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultra-Low Temperature Freezer
iUF118-GX
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.